BDNF gene methylation in brain of suicide subjects by Keller, Simona
 1 
UNIVERSITA’ DEGLI STUDI DI NAPOLI 
“FEDERICO II” 
 
 
 
 
Dottorato di ricerca in  
 
 
Medicina Molecolare e Genetica Medica  
XXII Ciclo 
 
 
 
 
BDNF GENE METHYLATION IN BRAIN OF 
SUICIDE SUBJECTS 
 
 
 
 
 
 
Docente Guida      Dottoranda 
Prof. Lorenzo Chiariotti      Simona Keller 
 
 
 
 
 2 
INDEX 
 
Introduction         pag. 1 
 
Overview of epigenetics 
 
Environment, epigenetics and human behaviour 
 
Epigenetics of neuropsychiatric disorders 
 
May depression have an epigenetic origin? 
 
Suicide 
 
 
The role of neurotrophins in the sucide 
 
Function of neutrophins and their receptors (TrKs) in brain development 
 
Structure of BDNF gene 
 
BDNF gene and Suicide 
 
 
Aim of the thesis  
 
 
Methods         pag. 17 
 
Study Subjects  
 
pH Measurement and Drung Analysis 
 
DNA and RNA extraction from tissues 
 
Bisulfite treatment 
 
DNA Methylation Analysis  
 
Pyrosequencing 
 
Bisulfite genomic sequencing 
 3 
 
SEQUENOM MassARRAY platform 
 
Real-time RT-PCR 
 
Statistical Analysis 
 
 
 
Results         pag. 24 
 
Methylation analysis of BDNF promoter IV in Wernicke’s area of 
suicide victims and normal control subjects 
 
Global genomic methylation analysis 
 
Relationship between BDNF expression and BDNF promoter IV 
methylation degree 
 
 
 
Comment         pag. 42 
 
 
 
References         pag. 46 
 
 
 
 1 
Introduction 
 
Overview of Epigenetics 
 
The word “epigenetic” has been used historically to refer to a heritable phenotype 
not coded by a change in DNA sequence. Cellular differentiation is a classic 
example in which epigenetic mechanisms play a critical role. Because all cells in 
an organism contain the same DNA, the ability to form distinct cell types with 
unique functions is achieved by the selective activation and silencing of individual 
genes across the genome. This epigenetic process is coordinated in large part 
through control of chromatin structure. Increasing evidence now indicates that 
changes in chromatin structure not only mediate these heritable epigenetic 
phenomena but also that the same types of changes in chromatin occur also in 
mature, postmitotic cells where they contribute to health and diseases (Nestrel 
2009). 
Related concepts are epialleles which refer to epigenetic variants of a genetic 
allele and epigenetic polymorphisms which have been described as variations of 
epigenetic patterns across individuals. For example, DNA methylation 
polymorphisms involve variations of DNA methylation across the genome. The 
concepts of the molecular aspects of epigenetics are evolving rapidly. Three 
molecular mechanisms, which interact with each other, have been shown to be 
involved. One is methylation of DNA which usually, but not always, depending 
on the position of the methylation change relative to the position of the 
transcription start site, inhibits gene transcription (Jone et al., 2001) DNA gets 
methylated at sites where there is cytosine by the enzymatic addition of a methyl 
group, using S-adenosylmethionine as the methyl group source, to the carbon-5 
position of cytosine. The majority of 5’-methylcytosine in mammalian DNA is 
present in 5’-CpG-3’ dinucleotides. Non-CpG sequences may also exhibit 
methylation, but generally at a much lower frequency (Castello et al., 2001). The 
methylation of CpG sites within the human genome is catalyzed by four well-
 2 
documented DNA methyltransferases (DNMTs) named DNMT1, DNMT2, 
DNMT3A and DNMT3B (Brueckner et al., 2004). DNA methylation has many 
functions like silencing of transposable elements, defense against viral sequences 
and transcriptional repression of certain genes. Eukaryotic DNA is intimately 
associated with proteins to form a highly ordered and condensed DNA: protein 
complex called chromatin. The most abundant proteins in chromatin are a family 
of small basic proteins called histones. Histones can be modified by different 
ways like acetylation, methylation, and phosphorylation of the histone tail 
domains. This alters chromatin structure, leading to regulation of gene 
transcription. Histone modifications lead to dynamic transitions between gene 
activation and silencing. These “on-off” transcription states are due to differences 
in histone modification leading to the formation of accessable, euchromatic (on) 
or condensed, heterochromatic (off) states (Jenuwein et al., 2001). A third 
epigenetic mechanism in gene expression has been described more recently: small 
RNAs derived from cleavage of double-stranded RNA can silente genes at 
transcriptional and post-transcriptional levels.Small RNAs are 21 to 28 
nucleotides long and include micro RNAs (miRNAs) and small interfering 
RNA(siRNAs). RNA-mediated gene silencing is important in maintaining 
chromosomal structure,genome defense and gene regulation (Almeida et al., 
2005). 
 
 
Environment, epigenetics and human behaviour. 
 
Common diseases involve interactions between genes and environment and 
epigenetic mechanisms are thought to be an interface between genes and the 
environment in psychiatric disorders (Bjornsson et al., 2004). The environmental 
factors may impinge on epigenetic mechanisms in gene expression by many ways. 
Thus, dietary levels of methionine, the metabolic precursor of  S-
adenosylmethionine during prenatal and early postnatal life, influences 
susceptibility  to chronic adult diseases because dietary methionine influences 
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DNA methylation. Environmental factors also modulate proteins like enzymes 
associated with DNA methylation and histone modification. Other proteins like 
polycomb proteins (proteins that maintain many genes important for development 
in a repressed state) also mediate the epigenetic effects of the environment on 
gene expression (Cao et al.,2002).  
Psychosocial factors have been described as important environmental factors 
involved in the pathogenesis of the idiopathic mental disorders and many 
experimental evidence from studies on animals that psychological factors can 
modify behaviour by epigenetic mechanisms. For example, it has been shown in 
cross-fostering studies in the rat, that non-genomic transmission of maternal 
behaviour and stress responses occur from one generation to the next (Francis et 
al., 1999). In two strains of inbred mice it was shown that strain-related 
behavioral differences may result from environmental factors acting during 
prenatal and postnatal development, rather than from genetic differences in the 
offspring. In a study conducted on pup licking and grooming by rat mothers 
(Weaver et al., 2004), increased frequency of these maternal behaviours increased 
the number of hippocampal glucocorticoid receptors in the pups, causing better 
regulation of glucocorticoid secretion.  
The increased glucocorticoid receptors in the pups were due to changes in DNA 
methylation and histone acetylation associated with the glucocorticoid receptor 
gene promoter. These differences emerged over the first week of life, were 
reversed with cross-fostering, and persisted into adulthood.  
Very interestingly, hypermethylation of  glucocorticoid receptor was also 
observed in human brain in subjects that had received childhood abuse 
(McGowan et al., 2009.) , thus translating in humans what previously observed in 
rat. 
Other clear evidences demonstrating that environment exposure is able to drive 
methylation changes in humans come from the milestones works addressing the 
phenotipic differences in monozygotic (MZ) twins. 
Recent studies showed that although twins are epigenetically indistinguishable 
during the early years of life, older monozygous twins exhibited remarkable 
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differences in their overall content and genomic distribution of 5-methylcytosine 
DNA and histone acetylation, affecting their gene-expression portrait. These 
findings indicate how an appreciation of epigenetics in missing from our 
understanding of how different phenotypes can be originated from the same 
genotype.   
It is also worth to note that monozygotic twins sharing the same experiences show 
much more similarities in epigenetic patterns during the life with respect of MZ 
twins that have lived apart (Fraga et al., 2005). 
 
 
Epigenetics of neuropsychiatric disorders 
 
Pathophysiological changes in the brain that are associated with psychiatric 
disorders or animal models of these conditions include gross differences in the 
sizes of specific brain regions, alterations in the morphology of subpopulations of 
neurons, neurochemical changes at the synaptic cleft, alterations in intracellular 
signalling and changes in the regulation of gene expression. Most psychiatric 
disorders share important features, including a substantial genetic predisposition 
and a contribution from environmental factors (Kendler et al., 2001). Another 
common attribute of psychiatric conditions is long-lasting behavioural 
abnormalities. An important challenge in psychiatric research has been to identify 
the molecular basis of stable changes in behaviour that account for both the 
symptoms of mental illness and their reversal during treatment. The regulation of 
gene expression has been proposed as one molecular mechanism that could 
mediate stable adaptations and maladaptations in the brain (Hyman et al., 1993). 
Changes in mRNA levels have been documented in specific brain regions both in 
animal models of psychiatric illness and in human brains, and have been related to 
altered behaviour. However, it has been difficult to identify the molecular 
mechanisms that underlie such stable changes in gene expression; virtually all 
reported changes in transcription factors and other nuclear regulatory proteins in 
animal models revert to normal within hours or days of chronic perturbation. 
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Recent research has raised the notion that epigenetic mechanisms, which exert 
lasting control over gene expression without altering the genetic code, could 
mediate stable changes in brain function. Historically, the field of epigenetics has 
focused on how cellular traits can be inherited without a change in DNA 
sequence. Studies of epigenetic mechanisms that underlie heritable transmission 
have flourished in the fields of developmental and cancer biology, where the 
continuity of unique patterns of gene expression between parent and daughter 
cells is crucial. These studies have converged on a set of common enzymatic 
modifications to chromatin structure that can up or down regulate gene expression 
in a manner that is transmissible to daughter cells. These mechanisms also 
regulate gene expression in neurons, but, as most neurons do not divide, 
chromatin modifications are instead sustained within individual cells. 
Recent discoveries show that the epigenetic regulation of neurobiological 
adaptations are associated with long-lasting behaviours in animal models of 
psychiatric conditions and in the brains of humans with these disorders. There are 
plenty of recent evidences indicating that altered methylation is present in brains 
of schizophrenic or bipolar patient. Some genes have been found aberrantly 
hypermethylated and underexpressed in schizophrenic or bipolar subjects 
compared to normal control. These genes are very important for the main 
pathways regulating neuronal plasticity and emotional responses such 
dopaminergic, serotoninergic and gabaergic systems.  
Many work have focused on epigenetic alterations at the reelin promoter gene. 
Post-mortem studies of patients with schizophrenia reveal significant down-
regulation of reelin expression in several brain regions that is not associated with 
neuronal loss. The reelin promoter contains a large CpG island, indicating that 
DNA methylation might be important for regulating its exspression. Furthermore, 
in recent postemortem studies on brain from person diagnosed with 
schizopherenia revealed that expression of glutamic acid decarboxylase 67 
(GAD67), an enzyme critical for synthesis of the inhibitory neurotransmitter 
GABA, is significantly reduced in interneurons.  Animal models of reelin 
haploinsufficiency exhibit reduced GABAergic inhibitory tone and a deficit in 
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sensorimotor gating, hallmarks of schizophrenia (Tueting et al., 1999; Qui et al ., 
2006). As a whole, these results suggest that an aberrant decrease in reelin and 
GAD67 gene expression could contribute to the pathogenesis of schizophrenia 
(Jonathan 2006). 
Moreover DNA methylation defects have been linked to members of a large group 
of human neuropsychiatric diseases that are associated with triplets instability. 
Recently, an aberrant CpG methylation has been identified in the first intron of 
FXN gene, upstream from the triplet expansion,  in patients with Friedrereich 
Ataxia. In particular, our group found hypermethylation of the region in four 
FRDA patients compared with four healthy subjects. In this study we found a 
strong correlation between CpG methylation degree of specific CpG sites with 
both the size of the triplet expansion and the age of onset (Castaldo et al., 2008).  
 
 
May depression have an epigenetic origin? 
The potential role of epigenetic alteration as cause of depression has been studied 
both in animal model and in humans.  
Chronic social defeat stress, an animal model of depression that mimics many 
kind of human depression, also alters chromatin regulation of BDNF gene. 
Prolonged exposure to an aggressor induces lasting changes in mouse behaviour 
such as social avoidance, which are reversed by cronic treatment with 
antidepressants. At a molecular level, chronic dafeat stress in mice induce 
substained downregulation of the expression of two variants of BDNF, BDNF III 
and BDNF IV, in the hippocampus. These changes are reversed only after 
treatment with the antipressant imipramine. Chronic defeat stress induces robust 
and long-lasting increases in H3-K27 dimethylation, a repressive modification, 
specifically at the promoters of the downregulated BDNF trascripts. 
In humans, mood disorders are among the most prevalent forms of mental illness. 
Severe forms of depression affect 2%–5% of the U.S. population, and up to 20% 
of the population suffer from milder forms of the illness. Depressionis almost 
twice as common in females than males. Another roughly 1%–2% are afflicted by 
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bipolar disdisorder (also known as manic-depressive illness),which affects 
females and males equally. Mood disorders are recurrent, life threatening (due to 
the risk for suicide), and a major cause of morbidity worldwide (Blazer et 
al.,2000). Depression has been described by mankind for several millenia. Most 
of the major symptoms of depression observed today were recognized in ancient 
times, as were the contributions of innate predispositions and external factors in 
causing the illness.The accients also recognized a large overlap of depression with 
anxiety and excessive alcohol consumption, both of which are well established 
today. Indeed, similarities between ancient descriptions of depression and those of 
the modern era are striking, yet it wasn’t until the middle part of the 19 th century 
that the brain became the focus of efforts understand the pathophysiology of this 
disorder.  
Epidemiologic studies show that roughly 40%–50% of the risk for depression is 
genetic (Sanders et al.,1999; Fava and Kendler, 2000). This makes depression a 
highly heritable disorder, at least as heritable as several mon complex medical 
conditions (type II diabetes, hypertension,asthma, certain cancers), which are 
often thought of as genetic. Yet, the search for specific genes that confer this risk 
has been frustrating, with no genetic abnormality being identified to date with 
certainty. The difficulty in finding depression vulnerability genes parallels the 
difficulty in finding genes for other psychiatric disorders and, in fact, for most 
common complex disdisordereases. There are many reasons for this difficulty, 
whichare reviewed elsewhere (Burmeister et al.,1999), including the fact that 
depression is a complex phenomenon with many genes possibly involved. Thus, 
any single gene might produce a relatively small effect and would therefore be 
difficult to detect experimentally. It is also possible that variants in different genes 
may contribute to depression in each family, which further complicates the search 
for depression genes.In addition, vulnerability to depression is only partly genetic, 
with no genetic factors also being important. Nongenetic factors as diverse as 
stress and emotional trauma, viral infections, and even stocastic (or random) 
processes during brain development have been implicated in the etiology of 
depression (Akibetweenskal et al.,2000; Fava and Kendler, 2000). Depressive 
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syndromes, indistinguishable from major depression defined by DSMIV and by 
their response to standard antidepressant treatments, occur in the context of 
innumerable medical conditions such as endocrine disturbances (hyper- or 
hypocortisolemia, hyper- or hypothyroidism), collagen vascular diseases, 
Parkinson’s disease, traumatic head injury, certain cancers, asthma, diabetes,and 
stroke.The role of stress warrants particular comment. Depression is often 
described as a stress-related disorder, and there is good evidence that episodes of 
depression often occur in the context of some form of stress. However,  stress per 
se is not sufficient to cause depression. Most people do not become depressed 
after serious stressful experiences, whereas many who do become depressed so 
after stresses that for most people are quite mild. Conversely, severe, horrendous 
stress, such as that experienced during combat, rape, or physical antidepresabuse, 
does not typically induce depression, but instead causes post-traumatic stress 
disorder (PTSD) that is distinct from depression based on symptomatology, 
treatment, and longitudinal course of illness. This underscores the view that 
depression in most people is caused by interactions between a genetic 
predisposition and some environmental factors, which makes the mechanisms of 
such interactions an important focus of investigation (Nestler et al., 2002). 
 
 
Suicide  
 
Depression is associated with an increased number of suicide attempts and 
increased lethality (Bostwick et al., 2000; Soloff et al., 2000). Suicide accounts 
for almost 2% of the world’s deaths. In most of the developed world, suicide is 
among the top 10 leading causes of death for individuals of all ages, and is the 
third leading cause of death among adolescents, after motor vehicle accidents and 
homicide (Mao et al.,1990; Mann et al., 2002). Several arguments suggest that 
suicidal behavior is a disorder of its own, although psychiatric disturbances, 
including depression, are major contributing factors. Autopsy studies of suicide 
victims have identified a high rate of major depressive disorder (MDD) as one of 
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the main causes of increased mortality among suicide victims. The presence of 
psychopathology is a strong predictor; however, only a minority of people with 
such diagnoses commits suicide, which indicates that there is a certain 
predisposition to suicide that is independent of the main psychiatric disorders 
(Mann et al.,;1998; Turecki et al., 2005). Despite the devastating impact of 
depression and suicide on numerous lives, there is still a dearth of knowledge 
concerning the mechanisms underlying their pathogenesis. Overwhelming 
evidence points to altered synaptic and structural plasticity in patients with 
depression and in suicidal patients. In fact, it has been proposed that 
depression/suicide results from an inability of the brain to make appropriate 
adaptive responses to environmental stimuli as a result of impaired synaptic 
plasticity and structural plasticity. Support for this comes from a variety of studies 
in major depressed/suicidal subjects demonstrating altered brain  structure, such 
as reduction in cell number, density, cell body size, neuronal and glial density in 
frontal cortical or hippocampal brain areas and decrease in parahippocampal 
cortex cortical/laminar thickness (Cotter  et al.,2001; Cotter et al., 2002; 
Rajkowska et al., 2007). Furthermore, depression is associated with negative 
impact on learning and memory; and stress, a major factor in depression and 
suicide, hinders performances on hippocampal-dependent memory tasks and 
impairs induction of hippocampal long-term potentiation. These studies clearly 
demonstrate impaired structural and functional plasticity in depression and 
suicide; however, the precise molecular and cellular nature of events that lead to 
such altered plasticity in these disorders remains unclear. Survival and 
development of neurons in the central nervous system (CNS) depends on the 
influence of a variety of extracellular signals. One set of signals is provided by 
neurotrophins. 
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The role of neurotrophins in the suicide  
 
Function of neurotrophins and their receptors (TrK) in brain 
development  
 
The role of neurotrophins in directing brain growth and neuronal functioning is 
being increasingly recognized. Neurotrophins not only play an important role in 
cellular proliferation, migration, and phenotypic differentiation and/or 
maintenance in the developing central nervous system, CNS (Lewin et al., 1996; 
McAllister et al., 2001), but their presence is required in the adult CNS for 
maintenance of neuronal functions, structural integrity of neurons, and 
neurogenesis (Sofroniew et al., 1990; Cooper  et al., 1996) which suggests that 
neurotrophins are biologically significant over the entire life span. In addition, a 
number of studies have demonstrated that neurotrophic factors regulate structural, 
synaptic, and morphological plasticity to modulate the strength or number of 
synaptic connections and neurotransmission (McAllister  et al., 1999; Thoenen  et 
al., ;2000). Thus, a pathological alteration of the neurotrophic factor system may 
not only lead to defects in neural maintenance and regeneration and, therefore, 
structural abnormalities in the brain, but may also reduce neural plasticity and, 
therefore, impair the individual’s ability to adapt to crisis situations. 
Mammalian neurotrophins are homodimeric proteins that include nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT) 3, 
and NT 4/5. Most functions of neurotrophins are mediated by the tropomycin 
receptor kinase (Trk) family of tyrosine kinase receptors. The interaction of 
neurotrophins with the Trk receptors is specific: NGF binds with TrkA, BDNF 
and NT 4 both bind with TrkB, and NT 3 binds with the highest affinity to TrkC 
but is also capable of signaling through TrkA and TrkB. In addition to the full 
length TrkB receptor, several noncatalytic truncated TrkB isoforms have also 
been identified; these isoforms lack the signaling domain, preventing the 
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induction of a signal transduction mechanism. Binding of a neurotrophin to the 
appropriate Trk receptor leads to the dimerization and transphosphorylation of 
tyrosine residues in the intracellular domain of the Trk receptors and subsequent 
activation of cytoplasmic signaling pathways (Chao et al., 2006; Reichardt et al., 
2006).  
Of various neurotrophins, BDNF has attracted a great deal of interest as a 
functional candidate gene in various mental disorders. The Bdnf gene lies on the 
reverse strand of chromosome 11p13 and encodes a precursor peptide pro-
BDNF(Seidah et al.,1996). In fact, all neurotrophins, including BDNF, are 
synthesized as a pre-pro-neurotrophin precursor that undergo post translational 
modifications before giving rise to mature homodimeric protein. The pro-BDNF 
is produced in endoplasmic reticulum, which is accumulated in trans-Golgi 
network via Golgi apparatus. It has been suggested that pro-BDNF binds to 
sortilin in the Golgi, which facilitates the correct folding of the mature domain. 
The mature domain of BDNF binds to carboxypeptidase E, thereby sorting BDNF 
to the regulated secretary pathway (Lu et al., 2005). A substitution of valine (Val) 
to methionine (Met) at codon 66 in the prodomain impairs this sorting of BDNF 
(Egan et al., 2003). 
The expression of the BDNF gene is tightly regulated by neuronal activity, 
through mechanisms dependent on calcium (Mellstrom et al., 2004). 
In addition to BDNF, the function of  a receptor for BDNF is also regulated in an 
activity-dependent manner. TrkB is primarily localized in the synaptic sites. 
Further localization of  TrkB occurs at the synaptic sites after neuroanal activity. 
Neuronal activity, therefore, is critical for synthesis and intracellular targeting of 
TrkB receptors. Thus, BDNF release and expression of TrkB receptors in a 
coordinated fashion are important for optimal synaptic response (Lu et al., 2005). 
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Structure of BDNF gene  
 
Previous studies have revealed that the human BDNF gene consists of seven 
putative 5’ exons and one protein-coding exon (Liu et al., 2005; Aoyama et al., 
2001). However, the expression patterns of different exons have not been 
thoroughly studied and possible linkage of these exons to separate promoters has 
not been investigated. On the other side recent studies show that the human  
BDNF  gene, extending over 70 kb, contains 11 exons. The 3’ exon encodes all or 
most of the protein depending on the 5’ exon used. Independent of the 5’ exon 
usage, two separate polyadenylation signals in exon IX can beutilized in BDNF 
transcripts.  In addition, a new data showed that the human BDNF gene comprises 
nine functional promoters (Figure1). The structures of the human BDNF gene and 
transcripts determined in these study are in good agreement with the results 
obtained for the rat and mouse BDNF genes (Aid et al., 2007). Some differences 
are present, though. First, human BDNF contains two more exons than rodent 
BDNF. Compared to the rat and mouse genes (Aid et al., 2007) there is an 
additional exon, exon Vh, linked to a promoter between exons V and VI. Human 
BDNF exon VIIIh, which is not linked to a separate promoter, is also not present 
in rodent BDNF. Furthermore, cryptic splicing donor and acceptorsites are used in 
human exon IX leading to transcripts containing exons IXbd and IXabd. These 
transcripts have not been detected in rodents. All this adds more complexity to the 
regulation of human BDNF. Second, in most cases, the usage of alternative 
promoters in the human BDNF gene leads to the expression of transcripts with 
different 5’ UTRs and with the protein-coding region in the common 3’ exon IXd. 
However, usage of an alternative upstream in-frame translation start site 
containing exon I, VII, or VIII could potentially lead to human BDNF prepro-
proteins with longer N-termini. Only the translation initiation codon within exonI 
is characteristic of rodent BDNF genes, suggesting that there are more BDNF 
protein isoformsin human than in rodents. Third, although the transcription 
initiation sites are generally in good agreement with the respective regions in 
rodents, we identified more transcription start sitesfor human exons II and IV than 
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had been reported previously for the rodent BDNF respective exons. Fourth, in 
contrast to the rodent BDNF genes we found that exon VIII of the humanBDNF is 
not used as a 5’ exon as determined by the 5’ RACE analysis. We show that in 
human the rarely used exon VIII of BDNF is exclusively spliced to exon V. Exon 
V can also be spliced to exon IXd without including exon VIII. Exon VIII was not 
detected in any transcript other than the ones starting with exon V, pointing to a 
possible functional regulation between the usage of a certain promoter and 
subsequent splicing.This kind of splicing regulation is especially interesting 
provided the notion that exon VIII of BDNF contains one of the alternative ATGs 
that may lead to the synthesis of a prepro-BDNF protein with an alternative N-
terminus. 
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Figure 1. Structure and alternative transcripts of the human 
BDNF. 
Structure of human BDNF gene (top). Exons are shown as boxes and introns as 
lines. Filled boxes and open boxes indicate the translated regions of the exons and 
the untranslated regions of the exons, respectively. Arrows indicate the 
transcription start sites. ATG and TAG mark the positions of the translational start 
and stop codons, respectively. Vertical dashed lines indicate alternative splicing 
sites for the respective exons. BDNF exon IX is divided into regions “a”, “b”, “c”, 
and “d” as indicated in the box marking the position of exon IX.  Novel exons are 
in green (V), red (Vh), purple (VIII), and light blue (VIIIh). The red circle 
indicate the trascript studied in this work. Alternative transcripts of the human 
BDNF gene (bottom). 
 15 
BDNF gene and Suicide 
 
The role of BDNF in depression has gained broad attention because many pre-
clinical and clinical studies provide direct evidence suggesting that modulation in 
expression of BDNF could be involved in behavioral phenomenon associated with 
depression. Based on these studies, the neurotrophin hypothesis of depression was 
proposed, which suggests that stress and depression is associated with decreased 
expression of BDNF and that antidepressants alleviate depressive behavior by 
increasing its level (Duman et al., 2000; Duman et al., 2002). This is quite 
relevant given that BDNF plays a key role in development and survival of 
neurone in the central nervous system, that it is involved in synaptic plasticity 
and, as earlier mentioned, compromised synaptic and structural plasticity have 
been shown to be associated with depression. Because stress and depression are 
the major contributory factors in suicide, recently, a number of studies have 
attempted to investigate the role of BDNF in suicidal behavior. 
In adulthood, BDNF is involved in neural homeostasis and in processes related to 
neuronal plasticity and connectivity including learning and memory (Tyler et al., 
2002; Yamada et al., 2002), drug addiction (Bolanos et al., 2004), response to 
social stress, aggressiveness and anxiety-like behaviours (Berton et al., 2006; 
Tsankova et al., 2006).  Alteration of BDNF expression in specific neurons may 
reduce neural plasticity, therefore impairing the ability to respond to stressors, and 
contributes to different neurodegenerative and neuropsychiatric disorders.  
Recent studies demonstrate that BDNF levels are decreased in brain (prefrontal 
cortex, and hippocampus) of suicide victims (Dwivedi et al., 2003- 2005) 
suggesting that BDNF plays a role in the pathophysiological aspects of suicidal 
behaviour. The expression of human BDNF gene is controlled  by a complex 
regulatory region, well conserved in mouse and rat (Aid et al., 2007) that includes 
at least nine promoters each driving transcription of BDNF mRNA transcripts 
containing one of the nine 5’ noncoding exons. BDNF promoter IV has been 
shown to be highly regulated during development, and epigenetic mechanisms 
play a key role in such regulation (Dennis et al., 2005; Mellios et al., 2009). DNA 
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methylation state of CpG sites within mouse promoter/exon IV is correlated with 
the expression of BDNF in developing mouse forebrain. Very interestingly, the 
neuronal activity-dependent activation of BDNF gene is mediated by decreased 
CpG methylation of BDNF promoter IV and the release of a chromatin repressor 
complex containing MeCP2 methyl binding protein (Chen et al., 2003; Zhou et 
al., 2006). Moreover, promoter IV is the major target of chromatin changes 
associated with alteration of BDNF expression in mouse models of 
neuropsychiatric disorders (Tsankova et al., 2006 and 2007) However, no data on 
the methylation state of BDNF gene, either in human mental illness or in suicide 
victims, have been reported so far. 
 
 
Aim of the thesis 
 
In this work we tested the hypothesis that alteration of DNA methylation cuold be 
involved in the disregulation of BDNF gene expression in the brain of suicide 
subjects. To this aim, we analyzed, by three independent quantitive techniques, 
the DNA methylation degree of large region of human BDNF gene in post-
mortem brain (Wernicke’s area) of 44 suicide completers and 33 control subjects. 
We also determined the global DNA methylation state in the same samples and 
the BDNF mRNA levels in some samples that displayed different BDNF 
methylation degree. Our results showed that DNA methylation levels at BDNF 
promoter IV were increased in suicide victims compared to normal control 
subjects, irrespective of global DNA methylation degree, and that the amount of 
BDNF transcript IV was lower in samples displaying a higher BDNF promoter IV 
methylation. 
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Methods 
 
Study Subjects 
 
The study was performed on post-mortem samples of brain tissue extracted from 
the Wernicke area obtained from 44 suicide and 33 non suicide control subjects. 
Most of autoptic samples were collected within 12-26 hours of subject’s death 
(PMI information are reported in Table 1), in the course of autopsy at the Institute 
of Forensic Medicine, University of Ljubljana, in a period of time comprised 
between 1999 and 2005, and stored at -80°C c/o the Biological Bank of the 
Inštitut za Varovanje Zdravja, Ljubljana (Slovenia). This study was performed 
according to Ethical issues of such Institution. All studied subjects were of 
Caucasian ethnicity and all were right handed. A detailed description of the 
subjects analyzed in this study as data on subjects', sex, age and cause of death 
were gathered from the subject's record are reported in Table 1. Data on 
psychiatric diagnoses were obtained from the doctor's note for autopsy and in the 
cases in which coroner's inquest was done in the presence of relatives also their 
testimony was taken into consideration (Table 2 and Table 3). 
 
 
pH Measurement and Drug Analysis 
  
Blood was taken from the subjects in order to perform general toxicological 
screening using gas chromatography-mass spectrometry (GC-MS).   
The analysis of pH of the homogenate was performed using the automated 
analyzer 865 (Bayer, now Siemens). A 50-100 mg sample of liquid nitrogen 
pulverized tissue was mixed with distilled deinoinzed water in a 10% (W/V) 
solution. To confirm blood data we performed drug analysis also on homogenates, 
using the REMEDI column switching L C (Biorad Lab) which deteets about 700 
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drugs or metabolites including most of illicit substances and drungs of abuse or 
their diredt metabolites (Zhou et al.,  2006). 
 
 
DNA and RNA extraction from tissues  
 
DNA and RNA were extracted, from each sample, from a portion of liquid 
nitrogen pulverized tissue. DNA was preparated using QIAamp DNA Mini Kit 
(Qiagen) following the instruction manual. Total RNAs were extracted from 
tissues using TRI REAGENT (Invitrogen) solution, according to the 
manufacture’s instructions. The integrity of the RNA was assessed by denaturing 
agarose gel electrophoresis. RNA quality and quantity assessment was performed 
by ND-1000 NanoDROP spectrophotometer. All samples showed a quality ratio 
(260:280 – 260:230) between 1,8 and 2,2 which is considered optimal range 
(Tsankova et al., 2007). 
Negative controls were obtained by performing the PCR on samples that were not 
reversed-transcribed but otherwise identically processed.  
 
 
Bisulfite treatment 
 
Sodium bisulphite conversion of genomic DNA (2 mg) was obtained using 
Epitect Bisulphite kit (Qiagen) following the purchaser's instructions. Amplicons 
used for methylation analysis were obtained from 50 ng of bisulfite treated 
genomic DNA. 
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DNA Methylation analysis  
 
Pyrosequencing. Pyrosequencing technology  (Tost  et al., 2007) was used for 
DNA methylation quantitative analysis that was performed using the PSQ 96MA 
instrument from Pyrosequencing (Biotage AB, Uppsala, Sweden) following the 
manufacturers protocol. The reactions were  assayed on the PSQ 96MA using 
the SNP analysis software. Primers used for PCR were: BDNF FW1 (position 
from nucleotides -227 to -204) 5’-tttgTtggggTtggaagtgaaaaT-3’ (5’-Biotinylated); 
BDNF RV1 (from  +59 to +87) 5’-cccatcaacRaaaaactccatttaatctc-3’.  Capital T 
represent thymidines that derive from the the conversion of cytidines after 
bisulfite treatment while t represent original thymidines. R stands for G or A. 
Amplifications were carried out on 10 ng of bisulphite treated DNA using 
HotStarTaq DNA polymerase (Qiagen) under the following conditions: 15 min at 
95°C, followed by 50 cycles of 30 sec at 95°C, 52 sec at 59°C, and 1 min at 72°C, 
then a final elongation of 10 min at 72°C, in a final reaction volume of 30 ml. 
PCR final products (314 bp) were then used for Pyrosequencing reactions; 
sequencing primer (BDNF 2) was 5’-acaaaaaaatttcatactaa-3’ (position from +32 to 
+51). Target CpGs were evaluated by analysis of the resulting pyrograms. 
Guanine (since a reverse sequencing primer was used) was incorporated during 
pyrosequencing if the template CpG was methylated, while adenine was 
incorporated if the template CpG was unmethylated. Thus the proportion of G : A 
incorporated  is stoichiometrically proportional to the degree of methylation at 
that CpG site in the template DNA.  
Global DNA methylation analysis was performed using the PyroMarkTM LINE-1 
assay kit (BiotageAB, Uppsala, Sweden). Long Interspersed Nucleotide Elements 
(LINE-1) represent about 15% of human genome; thus, quantitative DNA 
methylation analysis of LINE-1 may be considered a surrogate analysis of global 
DNA methylation (Yang et al., 2004). The conditions and primers applied were 
according to manufacturer’s instructions. PCR Amplifications were carried out 
using the LINE-1 Forward and Reverse primers on 120 ng of bisulphite treated 
DNA, using HotStarTaq DNA polymerase (Qiagen), in a final reaction volume of 
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25 ml. Methylation was quantified by Pyrosequencing analysis using the 
sequencing primer provided by the LINE-1 assay reagent kit. 
Bisulphite genomic sequencing: 2 mL of each sample were used as template in 
PCR reactions using the following primers: BDNF FW2 5’- 
gggggaggattaaTtgagTTagttTtg -3’ (position from nucleotides -358 to -332) and 
BDNF RV2 5’- cccatcaacRaaaaactccatttaatctc -3’(from nucleotides +59 to +87), 
PCR final products (445 bp) were then used for the analysis of the BDNF 
promoter IV. Amplifications were  carried out on 10 ng of bisulphite treated DNA 
using HotStarTaq DNA polymerase (Qiagen) under the following conditions: 15 
min at 95°C, followed by 50 cycles of 30 sec at 95°C, 52 sec at 58,3°C, and 1 min 
at 72°C, then a final elongation of 10 min at 72°C before holding at 4°C, in a final 
reaction volume of 30 ml. Confirmation of PCR product quality and freedom from 
contamination was established on 2% agarose gels with ethidium bromide 
staining. PCR final products were then cloned into the pGEM-T-easy vector 
provided by Promega pGEM®-T-Easy Vector System II (Promega Italia, Milan, 
Italy) following the supplier’s procedures. Plasmid DNA was purified using the 
Qiagen plasmid Mini Kit. The purified plasmids were sequenced in both 
directions using T7 and Sp6 primers. At least 20 independent clones were 
sequenced to determine the methylation pattern of individual molecules (Lembo et 
al., 2003). Sequencing was performed at the CEINGE Sequencing Core Facility. 
SEQUENOM MassARRAY platform: This system utilizes MALDI-TOF mass 
spectrometry in combination with RNA base specific cleavage (MassCLEAVE). 
A detectable pattern is then analyzed for methylation status. PCR primers to 
analyze BDNF promoter IV (Upper and Lower strands), designed by using 
Methprimer (www.urogene.org/methprimer), were: L2F, 5’-
aggaagagagTTGATTTTTTTAGAGTTTGTTTAATAGGA-3’; L2R, 5’-
cagtaatacgactcactatagggagaaggctAACATAAAATCTCCCTACCTCTACC-3’; 
L1F, 5’-aggaagagagTGTATTTTTTTTGTTTTGTAGTAAAGAAGT-3’, L1R, 
cagtaatacgactcactatagggagaaggctAAAACTTTTTATTTATCTTAACTACCCTA
A; U2F, 5’-aggaagagagTTTTTTTGTTGTAGAATAGAAGGAGT-3’; U2R, 5’-
cagtaatacgactcactatagggagaaggctAAAAAACCCAAACAATAACAAACCT-3;  
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U1F, 5’-aggaagagagGGTTGGAAGTGAAAATATTTGTAAAAG-3’; U1R, 5’-
cagtaatacgactcactatagggagaaggctACTCCTTCTATTCTACAACAAAAAAAT-3’. 
For reverse primer, an additional T7 promoter tag for in vivo transcription was 
added, as well as a 10-mer tag on the forward primer to adjust for melting-
temperature differences. Sequences of these tags are indicated in lower case. The 
MassCLEAVE biochemistry was performed as previously described (Ehrich et 
al., 2005), Mass spectra were acquired by using a MassARRAY Compact 
MALDI-TOF (Sequenom) and spectra's methylation ratios were generated by the 
Epityper software v1.0 (Sequenom).  
Presence of CpG island in the genomic region analyzed was assessed by using 
CGplot software (http://www.ebi.ac.uk/emboss/cpgplot/). 
 
 
Real-time RT-PCR 
 
1 µg of total RNA of each sample was reverse-transcribed with the QuantiTect® 
Reverse Transcription (Qiagen) using an optimized blend of oligo-dT and random 
primers according to the manufacturer’s instructions. To design the qPCR assay 
we used a Human ProbeLibrayTM system (Exiqon, Denmark). Using the free 
ProbeFinder assay design software, which is an integrated part of the package, we 
chose the best probes and primers pair. To amplify a fragment for real time PCR 
of BDNF mRNA, we  entered its accession number (ENST00000395980) on the 
assay design page of the ProbeFinder software. ProbeFinder generated an intron-
spanning assay identifying the exon-exon boundaries within submitted transcript. 
We chose an amplicon of 112 nucleotides generated by a couple of primers 
located in the first exon of transcript originating by promoter IV and in the third 
common coding exon, respectively. The number of probe was “human 31” 
(according to the numbering of Exiquon’s Human ProbeLibrary kit) and the 
primer sequences were: BDNF forward 5’-gccttgatggttactttgacaag -3’; BDNF 
reverse 5’-agccttcatgcaaccaaagt -3’. The same procedure was used to choose both 
probes and primers for housekeeping genes: GAPDH, accession number 
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NM_002046,3, probe “60”; UBC, accession number ENSG00000150991, custom 
probe; HPRT1, accession number ENSG00000165704, probe “73”; and RNA 
Polymerase II (RP II), accession number X63564.1, probe “65”. The primers  
sequences were: GAPDH fw 5’-agccacatcgctcagacac -3’; GAPDH rv 5’-
gcccaatacgaccaaatcc-3’; UBC fw 5’- atttgggtcgcggttcttg -3’; UBC rv 5’-
tgccttgacattctcgatggt-3’; HPRT1 fw 5’-tgaccttgatttattttgcatacc-3’; HPRT1 rv 5’-
cgagcaagacgttcagtcct-3’; RP II fw 5’-tgtcattgcagaggatgtgaa-3’; RP II rv 5’-
gcccagacttctgcatgg-3’. 
Relative Quantitative TaqMan PCR was performed in Chromo4 Detector, MJ 
Research in 96-well plates using a final volume of 20 µl. For PCR we used 8 µl of 
2,5x RealMasterMixTM Probe ROX (Eppendorf AG, Germany) 200 nM of each 
primer, 200 nM probe and cDNA generated from 200 ng of total RNA. The 
conditions used for PCR were 2 min at 95°C, and then 45 cycles of 20 sec at 95°C 
and 1 min a 60°C. Each reaction was performed in duplicate.  
The strategy used for the normalization of quantitative real-time RT-PCR data 
was the use of geometric averaging of multiple internal control genes in according 
with the method proposed by Vandesompele et al. (20….) We have evaluated 4 
housekeeping genes (GAPDH, HPRT I, UBC and RP II) that represent accurate 
control for mRNA expression analysis of post-mortem brain samples. For each 
housekeeping gene we measured the gene-stability (M) and ranking them using 
the geNORM algorithm (Vandesompele et al 2002; Barrachina et al., 2006; 
Hanninen et al., 2009). Stepwise exclusion of the gene with the highest M value 
allowed ranking of the tested genes according to their expression stability. We 
applied at each sample the delta-Ct formula for transforming Ct values to relative 
quantities (Q = E (minCt - sampleCt)) as described (Vandesompele et al., 2002). We 
calculated the Normalization Factor (NF) based on the geometric mean of 
quantity obtained by the transformation of Ct data. A sample, arbitrarily chosen 
among control subjects RNAs (920/04), was used as a reference sample. 
Amplification over 32 cycles were considered out of linear range. (Soong et al., 
2003). 
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Statistical analysis 
 
We performed statistical analyses with the SPSS software package (version 13.0). 
We used the One-way variance analysis (ANOVA) to compare methylation levels 
between sample groups. p values <0.05 were considered statistically significant. 
Mann-Whitney U Test was used to compare non Gaussian distribution. ANCOVA 
was used to assess the possible influence of gender and age. 
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Results 
 
Extensive methylation analysis of BDNF promoter IV in Wernicke’s 
area of suicide victims and normal control subject. 
 
To investigate a possible correlation between DNA methylation state of BDNF 
gene and suicidal behaviour, we analyzed genomic DNA samples derived from 
post-mortem brain samples extracted from the Wernicke’s area of 44 suicide 
subjects (21 men and 23 women; age range 15 to 79 yrs) and 33 non suicide 
control (16 men and 17 women; age range 13 to 76 yrs). A detailed description of 
the subjects analyzed in this study is reported in Table 1,  psychiatric diagnoses, 
medication and toxicological findings are reported in Table 2 and Table 3. 
First the methylation analysis was peformed in a wide genomic region for both 
upper and lower strands, by two independent quantitative methylation analyses, 
bisulfite genomic sequencing (molecular cloning technique) and a mass 
spectrometry based methylation analysis (MassARRAY). These analyses were 
performed in a subgroup of subjects (24) including 13 suicide completers and 11 
control subjects of different ages and sex. We analyzed by bisulfite genomic 
sequencing the genomic region from –203 to +58 (upper strand) encompassing the 
TSS of the BDNF gene and including 16 CpG sites (Figure 2). The results showed 
that the analyzed BDNF gene region was mainly unmethylated or low methylated 
and that the differentially methylated sites were essentially those lying in the close 
proximity of TSS. The results indicated that sites +10, +16, +25 and +28 were 
differentially methylated between suicide and control subjects. In addition this 
analysis showed that CpG site -93 was hypermethylated in almost all samples 
irrespective of groups (suicide and control subjects), age or gender. Finally, by 
MassARRAY we analyzed the genomic region from -219 to + 405 on upper 
strand, including 30 CpG sites, and the region from -289 to +512 on lower strand, 
including 34 CpG sites (Figure 3). 
 25 
Table 1 . Description of the analyzed subjects 
SAMPLE 
ID TYPE AGE CAUSE OF DEATH PMI PH 
156/05 MC 13 external cause of death: assault  ≤24 5.5 
202/02 MC 20 transport accident  ≤24 - 
437/02 MC 20 sudden natural death  ≤24 - 
142/00 MC 45 sudden natural death  ≤24 6.8 
146/00 MC 47 external cause of accidental injury-fall  ≤24 - 
604/01 MC 20 transport accident  ≤24 - 
545/02 MC 20 accidental poisining by noxious substances  ≤24 6.9 
201/02 MC 60 natural heart death    24 6.5 
454/02 MC 62 sudden natural death  ≤24 7.1 
447/02 MC 55 external cause of accidental injury-accidental drowning 
   24 - 
471/02 MC 71 transport accident  ≤24 6.9 
487/02 MC 55 sudden natural death  ≤24 - 
576/02 MC 62 sudden natural death  ≤24 - 
626/02 MC 64 sudden natural death  ≤24 6.8 
708/02 MC 65 sudden natural death  ≤24 - 
457/02 MC 60 sudden natural death  ≤24 - 
72/00 FC 46 sudden natural death  ≤24 - 
138/00 FC 38 trombemboly  ≤24 - 
931/04 FC 42 transport accident  ≤24 6.9 
94/05 FC 21 sudden natural death  ≤24 7.1 
28/05 FC 44 complication of medical and surgical care  ≤24 7.0 
773/03 FC 39 transport accident  ≤24 6.8 
404/05 FC 34 transport accident    24 6.7 
372/05 FC 49 transport accident (byciclist)  ≤24 6.5 
136/00 FC 76 sudden natural death  ≤24 - 
149/05 FC 55 external cause of accidental injury-fall    24 7.1 
498/05 FC 65 transport accident  ≤24 7.2 
485/02 FC 64 external cause of accidental injury-accidental drowning 
 ≤24 - 
547/01 FC 76 trombemboly  ≤24 - 
907/04 FC 70 brain bleeding    24 7.0 
79/05 FC 53 trombemboly  ≤24 6.9 
882/04 FC 59 sudden natural death  ≤24 7.1 
593/02 FC 71 sudden natural death  ≤24 - 
674/04 MS 22 intention self harm-hanging  ≤24 7.0 
179/04 MS 15 intentional self harm-jump from high place  ≤24 6.7 
727/03 MS 19 intentional self harm-poisoning    24 7.0 
447/03 MS 23 intentional  self harm-shooting  ≤24 6.8 
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315/02 MS 22 intentional  self harm-shooting  ≤24 - 
920/04 MS 19 intentional  self harm-shooting    26 6.8 
1015/04 MS 19 intentional  self harm-shooting  ≤24 7.0 
578/02 MS 25 intentional  self harm-shooting    46 - 
110/04 MS 19 intentional self harm-jump under train  ≤24 6.9 
22/02 MS 60 intentional self harm-hanging  ≤24 - 
888/99 MS 24 intentional self harm-shooting  ≤24 - 
598/01 MS 19 intentional self harm-hanging  ≤24 - 
190/02 MS 52 intentional self harm-other poisoning  ≤24 - 
288/02 MS 52 intentional self harm-poisoning  ≤24 6.9 
371/02 MS 52 intentional self harm-hanging  ≤24 - 
199/02 MS 56 intentional self harm-jump from high place  ≤24 - 
665/01 MS 69 intentional self harm-hanging    24 6.7 
540/02 MS 77 intentional self harm-poisoning  ≤24 6.8 
579/02 MS 56 intentional self harm-hanging  ≤24 6.4 
555/02 MS 59 intentional self harm-poisoning  ≤24 6.8 
584/02 MS 56 intentional self harm-hanging  ≤24 - 
84/04 FS 44 intentional self harm-hanging  ≤24 7.1 
78/04 FS 27 intentional self harm-jump from high place  ≤24 5.9 
103/05 FS 21 intentional self harm-drowning    24 - 
515/01 FS 44 intentional self harm-poisoning  ≤24 - 
456/03 FS 49 intentional self harm-drowning    26 7.0 
703/02 FS 38 intentional self harm-jump from high place  ≤24 - 
617/03 FS 41 intentional self harm-cutting with sharp object  ≤24 7.1 
427/04 FS 25 intentional self harm-jump from high place  ≤24 6.9 
524/02 FS 21 intentional self harm-hanging  ≤24 - 
690/01 FS 15 intentional self harm-jump from high place    24  - 
799/04 FS 14 intention self harm-hanging  ≤24 6.8 
22/00 FS 28 intention self harm-shooting  ≤24 - 
101/00 FS 40 intentional self harm-jump from high place  ≤24 - 
63/02 FS 71 intentional self harm-hanging  ≤24 - 
108/02 FS 64 intentional self harm-poisoning  ≤24 - 
668/03 FS 57 intentional self harm-drowning  ≤24 6.9 
99/04 FS 58 intentional self harm-drowning  ≤24 6.8 
43/02 FS 65 intentional self harm-drowning  ≤24 - 
228/02 FS 71 intentional self harm-poisoning  ≤24 - 
259/02 FS 55 intentional self harm-hanging  ≤24 - 
498/02 FS 60 intentional self harm-poisoning  ≤24 - 
489/02 FS 79 intentional self harm-drowning  ≤24 - 
679/02 FS 51 intentional self harm-hanging  ≤24 - 
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Table 2. Relationship between psychiatric conditions and 
Methylation/Expression levels of BDNF gene in Suicide subjects. 
 
 
 
Table 3. Relationship between Drug use  and 
Methylation/Expression levels of BDNF gene in Suicide subjects 
 
Psychiatric diagnosis 
 
 
Total N° of 
subjects 
N° of subjects with 
Hypermethylation at BDNF 
gene 
Schizophrenia 
 
4 1 
Bipolar disorder 
 
2 0 
Major depressive 
disorders 
 
12 3 
Schizoaffective disorder 
 
2 0 
Other 
 
2 0 
No diagnosed psychiatric 
illness 
 
22 9 
Toxicological 
findings 
 
Total N° of 
subjects 
N° of subjects with 
Hypermethylation at BDNF 
gene 
CARBROMAL 
 
1 0 
ZOLPIDEM 
 
1 0 
OLANZEPINE 
 
1 0 
DIAZEPAM 
 
3 1 
IMIPRAMINE 
 
3 0 
CITALOPRAM 
 
6 2 
NONE 
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sites were essentially those lying in the close proximity of TSS. The results 
indicated that sites +10, +16, +25 and +28 were differentially methylated between 
suicide and control subjects. In addition this analysis showed that CpG site -93 
was hypermethylated in almost all samples irrespective of groups (suicide and 
control subjects), age or gender. Finally, by MassARRAY we analyzed the 
genomic region from -219 to + 405 on upper strand, including 30 CpG sites, and 
the region from -289 to +512 on lower strand, including 34 CpG sites (Figure 3). 
This analysis showed that also in this wider genomic region most of CpG sites 
were unmethylated or low methylated in both suicide and control subjects and 
that, on the upper strand, sites  +10, +16, +25 and +28 remain the differentially 
methylated CpG sites. Differences in methylation degree of these same sites 
detected on lower strand were slighter but a higher methylation level was detected 
at some of these CpG sites where the correspondent sites on upper strand were 
hypermethylated. Frequent hypermethylation of -93 on upper strand site was 
confirmed in these experiments. Slight differences in methylation degree at some 
CpG sites observed in the analysis performed by the different technical 
approaches were possibly due to the different sensitivity of the methods. Finally, 
we analyzed, by a further independent and very sensitive technique, the 
methylation status of four CpG sites (+10, +16, +25 and +28) located downstream 
the transcription initiation site of promoter IV of the BDNF gene (Figure 4A). 
These sites are embedded in a small CpG island (located from -99 to + 101) 
spanning the transcriptional start site (TSS). A quantitative methylation analysis 
was performed using the pyrosequencing technology in order to assess the precise 
degree of methylation of each CpG site. 
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Figure 2.  Methylation analysis by genomic bisulfite sequencing. Top: 
Diagramatic representation of BDNF gene (promoter/exon IV).  Regulatory 
upstream region (open box),  exon IV (black box) and intron IV (striped box) are 
indicated. Vertical bars represent the relative positions of each CpG site. TSS is 
indicated by an arrow.  The relative positions of the primer utilized for 
amplification (BDNF FW2 and BDNF RV2) are indicated. Bottom: The 
methylation degree of each CpG site (circles) is indicated by different colours as 
specified in the Figure.  SC = suicide completers; Controls = non suicide subjects. 
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Figure 3.  Methylation analysis by MassARRAY. Top: Diagramatic 
representation of BDNF gene (promoter/exon IV) as in Figure 4.  The relative 
positions of the primer utilized for amplification of amplicons U1 (upper strand  
from -218 to + 160), U2 (upper strand from +134 to +405), L1 (lower strand from 
-289 to  +163) and L2 (lower strand from +33  to  +512) are indicated by arrows 
on top. Bottom: Comprehensive view of methylation state of BDNF gene. The 
methylation degree of each CpG site (circles) belonging to the amplicons U1, U2, 
L1 and L2, is indicated by different colours as specified in the Figure. CpG sites 
analyzed by MALDI-TOF were 14/19 (U1), 7/11 (U2), 16/21 (L1) and 15/17 
(L2). For CpG sites not analyzable by the assay, data from other procedures or 
average of two adjacent CpG sites are indicated. Each subject is identified by 
sample ID. SC = suicide completers; Controls = non suicide subjects. 
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 A representative pyrogram is shown in Figure 1B. Full raw data, indicating the 
methylation degree of each CpG site in each sample, are reported in Table 4. The 
analysis was repeated three times and each value did not differ significantly (+/- 
0.7%). The mean methylation degree of the four CpG sites in each subject is also 
reported in Table 4 and graphically shown in Figure 5. Overall, the results showed 
that the mean methylation degree of the 4 CpG sites was always under 12.9% in 
the 33 non-sucide control subjects while, in 13/44 cases (30%) among the suicide 
victims, the mean methylation degree ranged between 13.1 and 34.2% (Figure 5 
and Table 4). In order to establish whether the observed differences in the mean 
methylation degree between suicide and non suicide subjects were statistically 
significant, we performed one-way variance analysis (ANOVA). As shown in 
Figure 6A, significant differences are clearly discernible in the mean methylation 
status of the region analyzed between cases and controls (One-way ANOVA, 
F=13.7, p<0.001). By the same method, we analyzed the relationship between the 
methylation degree of each of the four CpG sites and suicidal behaviour. 
Statistically significant differences between cases and control groups were found 
for the CpG sites +10 and +25 (Figure 6B). A similar, but not statistically 
significant, trend to hypermethylation was found for the other two CpG sites 
tested (+16 and + 28). We analyzed the data also by a non parametric test (Mann-
Whitney U Test) obtaining similar results. Statistically significant differences 
between cases and control groups were found for the average methylation of the 
region (Mann-Whitney U Test p = 0.001) and for CpG sites +10 and +25 (p = 
0.002 and 0.001 respectively). No effect of gender and age was found by 
ANCOVA analysis (data not shown). 
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Figure 4. Pyrosequencing analysis of BDNF gene. A: Structure of human BDNF 
gene, promoter IV. The transcriptional start site (+1) is indicated by an arrow. The  
positions of the CpGs analyzed (open circle) and of the primers used (arrows) for 
pyrosequencing analysis are indicated. BDNF FW1 (biotinylated) and BDNF 
RV1: amplification primers; BDNF S1: sequencing primer. B. Top panel: 
representative pyrogram for pyrosequencing analysis of BDNF. The four targeted 
cytosines are enclosed in shaded squares (as reverse strand was read, G peaks 
indicate methylated cytosine while A indicates unmethylated cytosine, and the 
order of the CpGs analyzed is inverted). Bottom panel: representative pyrogram of 
global methylation (LINE-1). Four CpG sites were analyzed (shaded squares); in 
this case as forward strand was read, C peaks indicate methylation while T peaks 
indicate no methylation. 
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Table 4.  Methylation analysis data. Degree of methylation of each of the four 
CpG sites analyzed, their average value, and degree of DNA global methylation 
for each sample are reported. 
 
SAMPLE 
ID 
SUBJECT 
CpG 
1 
CpG 
2 
CpG 
3 
CpG 
4 
AVERAGE 
156/05 MC 8,4 4,3 7,9 3,5 6,025 
202/02 MC 0 19 0 0 4,75 
437/02 MC 11,2 14 0 0 6,3 
142/00 MC 5,1 0 9,6 0 3,675 
146/00 MC 8,6 0 15 0 5,9 
604/01 MC 0 0 10,7 0 2,675 
545/02 MC 0 10,9 17,5 0 7,1 
201/02 MC 0 0 26,7 0 6,675 
454/02 MC 0 0 11 0 2,75 
447/02 MC 34,9 0 16,7 0 12,9 
471/02 MC 6,2 4,5 9,2 0 4,975 
487/02 MC 0 0 0 0 0 
576/02 MC 3,3 1,6 5,7 0 2,65 
626/02 MC 4 2,6 6,3 9,7 5,65 
708/02 MC 4,4 2 4,8 1,5 3,175 
457/02 MC 8,4 2,5 5,3 2,6 4,7 
72/00 FC 0 7,6 8,4 0 4 
138/00 FC 6,5 3,3 7 0 4,2 
931/04 FC 0 4,4 7,1 3 3,625 
94/05 FC 4,4 3,7 5,1 6,5 4,925 
28//05 FC 0 6,5 12,8 6,9 6,55 
773/03 FC 0 16,5 0 14,4 7,725 
404/05 FC 0 0 0 15 3,75 
372/05 FC 16,2 8,8 0 0 6,25 
136/00 FC 19 11,2 0 10,2 10,1 
149/05 FC 0 10,3 15,8 11,2 9,325 
498/05 FC 0 0 0 12,8 3,2 
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485/02 FC 0 0 0 7,7 1,925 
547/01 FC 0 0 13,1 7,6 5,175 
907/04 FC 6,8 5 10,6 0 5,6 
79/05 FC 0 0 12,8 0 3,2 
882/04 FC 3,8 2 4,8 0 2,65 
593/02 FC 12,4 10,7 12,1 7,2 10,6 
674/04 MS 19,7 8,4 24,7 9,7 15,625 
179/04 MS 11,2 6,8 11,8 0 7,45 
727/03 MS 37,1 0 47,2 0 21,075 
447/03 MS 45 25,6 42,2 24 34,2 
315/02 MS 0 0 0 0 0 
920/04 MS 5,8 4,3 6,9 0 4,25 
1015/04 MS 13 7,2 14,9 6,5 10,4 
578/02 MS 0 0 7,2 0 1,8 
110/04 MS 0 0 18,2 0 4,55 
22//02 MS 6,9 4,8 10,7 0 5,6 
888/99 MS 0 7,6 13,8 0 5,35 
598/01 MS 37,9 17,6 31,6 24,5 27,9 
190/02 MS 0 0 16,7 0 4,175 
288/02 MS 35,8 0 40,8 0 19,15 
371/02 MS 0 0 22,1 0 5,525 
199/02 MS 0 0 26,8 0 6,7 
665/01 MS 49,4 0 43,5 25 29,475 
540/02 MS 9,3 0 10,6 0 4,975 
579/02 MS 7,9 0 8,6 0 4,125 
555/02 MS 0 0 18,1 0 4,525 
584/02 MS 4,2 0 5 2 2,8 
84/04 FS 9,9 5,5 13,1 3,5 8 
78/04 FS 34,8 19,1 33,5 17,4 26,2 
103/05 FS 0 14,5 0 15,3 7,45 
515/01 FS 6,5 6,1 8,4 27,6 12,15 
456/03 FS 19,3 6,4 7,3 2,9 8,975 
703/02 FS 24,6 22,5 42,2 18,1 26,85 
617/03 FS 9,3 3,6 5,3 0 4,55 
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427/04 FS 4,9 2 7,4 59 18,325 
524/02 FS 5,6 2,7 10,6 0 4,725 
690/01 FS 9,6 0 8,3 0 4,475 
799/04 FS 8 5,6 8,9 3,8 6,575 
22/00 FS 17,6 0 20 0 9,4 
101/00 FS 16,6 14,6 17,1 10,4 14,675 
63/02 FS 13,9 0 18,4 0 8,075 
108/02 FS 10,5 0 11,2 0 5,425 
668/03 FS 3,6 0 6 4,1 3,425 
99/04 FS 0 12,7 18,4 11,5 10,65 
43/02 FS 27,6 25,1 0 21 18,425 
228/02 FS 0 17,6 0 16,3 8,475 
259/02 FS 36 4,6 6,2 5,7 13,125 
498/02 FS 22,6 8,8 16,9 8,9 14,3 
489/02 FS 9,5 4,8 13,4 4 7,925 
679/02 FS 10,7 7,8 9,8 0 7,075 
 
 
Sample ID: progressive number/year of death. Abbreviation used: MC, male-
control; MS, male-suicide victim; FC, female-control; FS, female-suicide victim.
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Figure 6.  Percentage of BDNF promoter IV methylation in sucide subjects and 
non suicide controls. For each sample the percentage of methylation represents the 
average of the methylation degree of the 4 CpG sites analyzed. Grey columns: 
control samples; black columns: suicide victims. 
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Figure 6. Statistical analysis of methylation status of 4 CpG residues in the 
region of the promoter IV of the BDNF gene in suicide and control subjects. a) 
Average methylation of the four CpGs. Values represent mean +/- SE. b) 
Methylation status of individual CpG. Values represent mean and 95% CI 
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Global genomic methylation analysis 
 
Next, because it is known that global DNA methylation state of specific brain’s 
areas could vary among individuals, we addressed the question whether an 
increased methylation degree of BDNF promoter/exon IV in sucide victims 
associates with higher methylation levels throughout the genome or whether it is a 
specific feature of the BDNF gene. For this purpose we studied global 
methylation in all suicide and control samples by quantitatively analyzing the 
methylation of the long interspersed nucleotide elements (LINE-1), using 
pyrosequencing. A representative pyrogram is shown in Figure 7. Results,  
indicate that global methylation ranged between 81% and 90% among individuals. 
However, no correlation was found between global methylation and BDNF 
promoter IV methylation degree (data not shown). Moreover, global methylation 
levels did not associate with suicidality, gender and age (data not shown). Finally, 
we verified whether psycopathological conditions or the past and actual use of 
specific medications, could influence the BDNF gene methylation state. Drug 
history examination indicated that no subject made use of psycoactive substances 
during life other than those detected by toxicological screens and reported in 
Table 2 and Table 3. We found no significant correlation between any of these 
variables and the methylation degree at BDNF promoter (Mann-Whitney U Test p 
= ns). Overall, our results show that the BDNF promoter/exon IV is 
hypermethylated in post-mortem brain Wernicke’area of suicide subjects 
compared to normal control subjects irrespective of global methylation levels, 
suggesting that a gene-specific increase in DNA methylation could cause or 
contribute to down-regulation of BDNF expression in suicide subjects. 
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Figure 7. Global DNA Methylation Analysis. Percent of global genomic dna 
methylation in brain  wernicke’s area of suicide and control subjects as assessed 
by line-1 pyrosequencing analysis. 
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Relationship between BDNF expression and BDNF promoter IV 
methylation degree.  
 
In order to assess whether hypermethylation of BDNF promoter IV (CpG sites 
+10, +16, +25 and +28) was associated to a decreased gene expression, we 
analyzed by real time RT-PCR the BDNF mRNA (transcript IV) levels in the 
same subgroup of subjects. We analyzed 13 samples from the suicide victims and 
11 from control subjects; in particular 10 samples (4 from suicide and 6 from 
control group) with low level of methylation at BDNF promoter IV, 9 samples (4 
from suicide and 5 from control group) showing intermediate methylation levels 
and 5 samples from suicide subjects with the highest methylation degree (Figure 
8). For this quantitative RT-PCR assay we used specific primers for the analysis 
of BDNF mRNA transcript originating from promoter IV. The analyzed samples 
showing a high methylation degree of BDNF promoter IV expressed lower levels 
of BDNF mRNA as compared to the low and medium methylated samples beeing 
the mildly methylated samples in the mid-range (Figure 8). 
Taken together, our data indicate that a higher methylation degree of BDNF 
promoter IV in brain (Wernicke’s area) correlates with suicidal behaviour and 
suggest that increased DNA methylation levels of BDNF promoter IV can 
negatively regulate BDNF expression.  
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Figure 8. Relative mRNA levels of BDNF transcript IV. The BDNF expression 
was normalized using 4 internal control genes (as described in Methods) and 
relative expression levels are shown. In parentheses, the pH value of each sample 
is indicated. No significant correlation was found between pH values and mRNA 
expression or methylation degree (Mann-Whitney U Test p = ns). The cut off line 
(bottom) indicates that detection was over 32 cycles. 
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Comment 
 
We analyzed, by three independent sensitive quantitative methods, the DNA 
methylation degree at BDNF promoter IV and the global DNA methylation levels 
in the brain (Wernicke’s area) of 44 suicide subjects and 33 non-suicide control 
subjects. The main conclusions of our work are: i) suicide subjects showed a 
statistically significant increase of DNA methylation at BDNF promoter IV and 
higher methylation degree corresponded to lower BDNF transcript IV; ii) such 
increase in CpG methylation was gene-specific since it was not accompanied by 
an increase of global DNA methylation; iii) global DNA methylation levels in 
Wernicke’s area varied among individuals but did not correlate with suicidal 
behaviour, and were not dependent on gender or age. 
The present work and the relative conclusions represent an absolute novelty for 
several aspects. In fact, the present study is novel in examining the possibility that 
BDNF hypermethylation could be associated with suicidality. This study was 
performed on samples of brain tissue obtained from the Wernicke’s area of 
suicide completers and control subjects who died for other causes. Wernicke’s 
area has been chosen for its function in understanding word meaning and 
semantic thinking and for its critical involvment with human language and with 
associative and integrative functions. This fact is consistent with several findings 
of neurocognitive alterations in suicide attempters, such as an impairment in 
decision making (Jollant et al., 2005, 2007) and problem solving (Speckens et al., 
2005) Wernicke’s area and its connections with other brain structures represent a 
unique feature of human brain, as suicidal behaviour is peculiar to humans, and 
may influence many factors including human social behavior (Rilling et al.,2008). 
Completed suicide cannot be considered a sudden and casual death but is the 
outcome of a process which involves a wide spectrum of thoughts, 
communications and acts. It is consistent with this assumption that in suicidal 
behaviour gene expression may be altered in a cortical area which has a highly 
specialized integrative and associative functions. Moreover post-mortem studies 
reported an age-related expression of BDNF in the temporal cortex (Webster et 
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al., 2006), suggesting that this neurotrophin is important in the early development 
of the temporal cortex. Suicidal behaviour has been found to be associated with 
early traumatic experiences and this link could be based on early modifications in 
the expression of the BDNF gene. 
The choice to analyze the methylation state of BDNF gene derived from previous 
evidences that BDNF mRNA and protein levels are decreased in different post-
mortem brain’s areas (hyppocampus and frontal cortex) (Dwivedi et al., 
2003,2005) and in plasma (Kim et al., 2007) of suicide victims compared to non 
suicide controls. Human BDNF expression is controlled by a very complex 
regulatory region including nine different transcription initiation sites driven by 
corresponding promoters (Pruunsild et al., 2007). We chose to analyze DNA 
methylation of promoter IV because it has been previously established that the 
equivalent rat and murine promoters are strongly regulated during development 
and in adult neurons and that epigenetic mechanisms play a critical role in such 
transcriptional regulation (Tsankova et al., 2009; Dennis et al., 2005; Mellios et 
al., 2009). Of particular relevance are the observations that the epigenetic state of 
promoter IV may be also modulated in mouse and rat brain by several exogenous 
factors such as membrane depolarization-induced calcium influx (Chen et al., 
2003; Zhou et al., 2006) chronic social defeat stress and antidepressant 
administration (Tsankova et al., 2006). These observations reinforce the growing 
hypothesis that complex epigenetic mechanisms, which may be modified by 
environment and may regulate gene activity without altering the DNA code, have 
long-lasting effects within mature neurons and are implicated in the regulation of 
human complex behaviour, including psychiatric disorders (Tsankova et al., 2007; 
Onishchenko et al., 2008; Szyf et al., 2008) Maya Vetencourt et al (Maya 
Vetencourt et al., 2008) showed that cortical administration of diazepam prevents 
the fluoxetin-mediated BDNF activation in the visual cortex raising the interesting 
question whether changes of BDNF expression or methylation state in suicide 
subjects may be influenced by drug consumption. However, in this study we did 
not find any relationship between BDNF methylation or expression with 
diazepam or fluoexetin consumption of the study subjects. McGowan et al. 
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(McGowan et al., 2008)  demonstrated that in the brain of 11 suicide subjects with 
history of early childhood abuse, the rRNA gene was downregulated and 
hypermethylated compared to control subjects. Very interestingly, Ernst et al. 
(Ernst et al., 2009) found that trkB is hypermethylated in sucide completers in 
different brain’s areas. Our study, that relates BDNF gene methylation state to 
suicidal behaviour, strongly supports the conclusions of these studies and provides 
a possible mechanism responsible for the reduction of BDNF levels observed in 
the brain of suicide subjects. In the near future it will be very interesting to extend 
the methylation analysis of BDNF gene to other brain’s areas involved in suicidal 
behaviour.  
Previous studies revealed that the methylation state of specific CpG sites in the 
BDNF rat and mouse promoter IV may play a critical role in BDNF gene 
regulation.  In particular, it has been shown that the CpG sites -128 and +19 of the 
rat BDNF promoter IV may mediate, when methylated, the binding to MeCP2 
which, in turn, is responsible for trascriptional repression (Chen et al., 2003; Zhou 
et al., 2006). However, the role of DNA methylation in the control of BDNF 
expression has not been previously investigated in human tissues. In the present 
work we show that CpG sites adjacent to the TSS of human BDNF transcript IV 
may play a role in the regulation of BDNF expression. In particular, statistical 
analysis showed that the methylation state of CpG sites +10 and +25 associates 
with suicidal behaviour. Moreover, we showed that an higher methylation degree 
of these sites is associated with lower BDNF mRNA levels suggesting that, at 
least in part, DNA methylation is involved in BDNF transcriptional regulation in 
human brain. Because we found much lower BDNF trancript IV mRNA levels in 
samples showing 20-30% methylation of four CpG sites in BDNF promoter IV 
compared to samples showing 3-5% methylation, we hypothesize that other 
mechanisms, including additional epigenetic mechanisms and/or lack of 
transcription factors, may contribute to such a strong repression. In the near 
future, it will be very interesting to determine the relative role, in the regulation of 
BDNF expression, of CpG sites lying in the different BDNF gene promoters in 
order to study the possible association of epigenetic state of other promoters with 
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suicidal behaviour. DNA methylation and other epigenetic factors could also 
provide some explanation to reported conflicting data on the association of the 
BDNF gene polymorphims with suicidal behaviour. 
In this study, we found a relatively low rate of suicide completers with a 
psychiatric disease. It cannot be excluded that in a few cases psychiatric 
conditions were present but were undiagnosed. However, the rate of diagnosed 
psychiatric diseases among suicide completers in our sample is comparable to the 
rate reported by other studies (Rockett et al., 2009). Moreover, the geographical 
region where the sample was collected has high suicide rates and it has been 
suggested that genetic component(s) might have an effect on increased suicide 
rates (Marusic et al., 2005). This genetic component possibly acts through 
personality features such as impulsive aggression. Overall, our study reinforces 
the mounting hypothesis that DNA methylation is involved in psychiatric 
conditions and deviant human behaviours and represents one of the first 
demonstration that alteration of gene-specific DNA methylation in human brain 
associates with suicidal behaviour. 
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